Alafi Capital holds 19.9% stake in CalciMedica

Rhea-AI Filing Summary

CalciMedica, Inc. (CALC) received an updated Schedule 13D from Alafi Capital Company LLC and Christopher D. Alafi reporting their beneficial ownership of 7,220,101 shares of common stock and related warrants, representing 19.9% of the class based on 34,141,460 shares outstanding as of August 20, 2026.

The position includes 5,112,345 common shares plus multiple warrant series. On August 19, 2026, after Stockholder Approval, the reporting persons received 3,529,192 Series A Warrants and 3,529,192 Series B Warrants. Due to a 19.99% beneficial ownership limitation, 2,605,965 Series A Warrants and 2,605,965 Series B Warrants are not currently exercisable. The filing states the amendment’s purpose is solely to reflect this warrant issuance, with no stated change in transaction purpose.

Key Figures

Beneficial ownership: 7,220,101 shares Ownership percentage: 19.9% Shares outstanding: 34,141,460 shares +5 more

8 metrics

Beneficial ownership 7,220,101 shares Shares of CalciMedica common stock and warrants beneficially owned by each reporting person

Ownership percentage 19.9% Percent of CalciMedica common stock class represented by the 7,220,101 shares

Shares outstanding 34,141,460 shares CalciMedica common stock outstanding as of August 20, 2026 used in ownership calculation

Common shares held 5,112,345 shares Common stock held directly by the reporting persons

Warrants at $7.15 130,651 warrants Warrants to purchase common stock at an exercise price of $7.15

Warrants at $0.8033 923,227 warrants Warrants to purchase common stock at an exercise price of $0.8033

Warrants at $1.00 923,227 warrants Warrants to purchase common stock at an exercise price of $1.00

New Series A and B Warrants 3,529,192 Series A and 3,529,192 Series B Warrants Warrants received on August 19, 2026 following Stockholder Approval

Key Terms

beneficial ownership limitation, Series A Warrants, Series B Warrants, dispositive power, +1 more

5 terms

beneficial ownership limitation regulatory

"not currently exercisable due to the 19.99% beneficial ownership limitation included in such warrants"

A beneficial ownership limitation is a rule that caps the percentage of a company’s shares an investor can be treated as owning or controlling for voting, regulatory or tax purposes. It matters to investors because it can restrict how many shares a person or group can buy or vote, affect takeover chances, and influence share liquidity and value — like a speed limit that prevents any single driver from taking over the whole road.

Series A Warrants financial

"the Reporting Persons received 3,529,192 Series A Warrants and 3,529,192 Series B Warrants"

Series A warrants are financial tools that give the holder the right to buy shares of a company at a specific price within a certain period. They are often issued alongside investments to provide additional potential profit if the company's value increases. For investors, they can offer a chance to benefit from future growth without committing immediate capital to buying shares.

Series B Warrants financial

"the Reporting Persons received 3,529,192 Series A Warrants and 3,529,192 Series B Warrants"

Series B warrants are contracts issued alongside a company's Series B financing that give the holder the right to buy a set number of shares at a fixed price within a specified time. For investors, they matter because they can provide leveraged upside if the company grows, or they can dilute existing shareholders when exercised—like a coupon promising a future share at a known price that can add value or change ownership stakes.

dispositive power regulatory

"Number of Shares Beneficially Owned by Each Reporting Person With: Sole Dispositive Power"

Dispositive power is the authority to decide the final outcome of an asset, legal claim, contract, or corporate action — in effect the power to dispose of or resolve something. For investors it matters because whoever holds that authority can determine who gets paid, who controls an asset or vote, and how risks and returns are allocated; think of it like holding the key that lets you lock in the winner or loser in a deal.

pecuniary interest regulatory

"Except to the extent of his or its pecuniary interest therein, each Reporting Person disclaims"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What ownership stake in CALC is reported in this Schedule 13D/A?

The reporting persons disclose beneficial ownership of 7,220,101 shares of CalciMedica common stock and warrants, representing 19.9% of the class based on 34,141,460 shares outstanding as of August 20, 2026.

Who are the reporting persons in this CALC Schedule 13D/A amendment?

The reporting persons are Alafi Capital Company LLC and Christopher D. Alafi. Alafi Capital is organized in California, and Christopher D. Alafi is a United States citizen and managing member of Alafi Capital Company LLC.

What triggered this Amendment No. 1 to the CALC Schedule 13D?

The amendment was triggered solely to reflect that, on August 19, 2026, the reporting persons received 3,529,192 Series A Warrants and 3,529,192 Series B Warrants, following the receipt of Stockholder Approval.

How is the 7,220,101 CALC beneficial ownership position composed?

It includes 5,112,345 common shares, plus warrants: 130,651 at an exercise price of $7.15, 923,227 at $0.8033, and 923,227 at $1.00, all held by the reporting persons.

Which CALC warrants are not currently exercisable under the 13D/A?

The filing states that 2,605,965 Series A Warrants and 2,605,965 Series B Warrants are not currently exercisable because of a 19.99% beneficial ownership limitation included in those warrants.

Did the reporting persons report recent CALC share transactions besides the warrant issuance?

The filing states that, except for receiving the 3,529,192 Series A Warrants and 3,529,192 Series B Warrants on August 19, 2026, none of the reporting persons effected transactions in CalciMedica securities within the past 60 days.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/24/2026 - 05:02 PM EDT Accepted by SEC EDGAR 08/24/2026 - 05:02 PM EDT Learn about SEC filing dates

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13D

Under the Securities Exchange Act of 1934

(Amendment No. 1)

CalciMedica, Inc.

(Name of Issuer)

Common Stock, par value $0.0001 per share

(Title of Class of Securities)

38942Q202

(CUSIP Number)

Alafi Capital Company LLC
8 Admiral Drive, Suite 324,
Emeryville, CA, 94608
(510) 663-7426

Christopher D. Alafi
8 Admiral Drive, Suite 324,
Emeryville, CA, 94608
(510) 663-7426

Evan Ng
Dorsey & Whitney LLP, 430 Cowper Street, Suite 250
Palo Alto, CA, 94301
(650) 565-2252

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

08/19/2026

(Date of Event Which Requires Filing of This Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

schemaVersion:

SCHEDULE 13D

CUSIP Number(s): 38942Q202

1

Name of reporting person

Alafi Capital Company LLC

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

OO

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

CALIFORNIA

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 7,220,101.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 7,220,101.00

11

Aggregate amount beneficially owned by each reporting person

7,220,101.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

19.9 %

14

Type of Reporting Person (See Instructions)

OO

Comment for Type of Reporting Person:

Includes 5,112,345 shares of common stock held directly by the Reporting Person, 130,651 warrants to purchase common stock at an exercise price of $7.15, 923,227 warrants to purchase common stock at an exercise price of $0.8033 and 923,227 warrants to purchase common stock at an exercise price of $1.00 held by the Reporting Person. Does not include 2,605,965 Series A Warrants or 2,605,965 Series B Warrants that are not currently exercisable due to the 19.99% beneficial ownership imitation included in such warrants. The calculation of percentage ownership is based on a total of 34,141,460 shares of Issuer common stock as of August 20, 2026, as set forth by the Issuer plus the total possible warrants that could be exercised by the Reporting Person.

SCHEDULE 13D

CUSIP Number(s): 38942Q202

1

Name of reporting person

Christopher D. Alafi

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

OO

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 7,220,101.00
8	Shared Voting Power 0.00
9	Sole Dispositive Power 7,220,101.00
10	Shared Dispositive Power 0.00

11

Aggregate amount beneficially owned by each reporting person

7,220,101.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

19.9 %

14

Type of Reporting Person (See Instructions)

IN

Comment for Type of Reporting Person:

Includes 5,112,345 shares of common stock held directly by the Reporting Person, 130,651 warrants to purchase common stock at an exercise price of $7.15, 923,227 warrants to purchase common stock at an exercise price of $0.8033 and 923,227 warrants to purchase common stock at an exercise price of $1.00 held by the Reporting Person. Does not include 2,605,965 Series A Warrants or 2,605,965 Series B Warrants that are not currently exercisable due to the 19.99% beneficial ownership imitation included in such warrants. The calculation of percentage ownership is based on a total of 34,141,460 shares of Issuer common stock as of August 20, 2026, as set forth by the Issuer plus the total possible warrants that could be exercised by the Reporting Person.

SCHEDULE 13D

Item 1.	Security and Issuer
(a)	Title of Class of Securities: Common Stock, par value $0.0001 per share
(b)	Name of Issuer: CalciMedica, Inc.
(c)	Address of Issuer's Principal Executive Offices: 505 Coast Boulevard South Suite 307, La Jolla, CALIFORNIA , 92037.
Item 1 Comment: The following constitutes Amendment No. 1 to the Schedule 13D filed by the undersigned ("Amendment No. 1"). This Amendment No. 1 amends the Schedule 13D as specifically set forth herein. This Amendment No. 1 was triggered solely to reflect the issuance of warrants to the Reporting Persons on August 19, 2026.
Item 4.	Purpose of Transaction
	None
Item 5.	Interest in Securities of the Issuer
(a)	See Items 7-11 of the cover pages of this Statement and Item 2 above. Except to the extent of his or its pecuniary interest therein, each Reporting Person disclaims beneficial ownership of such shares of Common Stock, except for the shares, if any, such Reporting Person holds of record. This Amendment No. 1 is being filed to report that, on August 19, 2026, the Reporting Persons received 3,529,192 Series A Warrants and 3,529,192 Series B Warrants, following the receipt of Stockholder Approval.
(b)	See Items 7-11 of the cover pages of this Statement and Item 2 above. Except to the extent of his or its pecuniary interest therein, each Reporting Person disclaims beneficial ownership of such shares of Common Stock, except for the shares, if any, such Reporting Person holds of record. This Amendment No. 1 is being filed to report that, on August 19, 2026, the Reporting Persons received 3,529,192 Series A Warrants and 3,529,192 Series B Warrants, following the receipt of Stockholder Approval.
(c)	This Amendment No. 1 is being filed to report that, on August 19, 2026, the Reporting Persons received 3,529,192 Series A Warrants and 3,529,192 Series B Warrants, following the receipt of Stockholder Approval. Except as reported in this Statement, none of the Reporting Persons has effected any transactions in the Issuer's securities within the past 60 days.
(d)	Not applicable.
(e)	Not applicable.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Alafi Capital Company LLC

Signature:	/s/ Christopher D. Alafi
Name/Title:	Christopher D. Alafi, as managing member of Alafi Capital Company, LLC
Date:	08/24/2026

Christopher D. Alafi

Signature:	/s/ Christopher D. Alafi
Name/Title:	Christopher D. Alafi
Date:	08/24/2026